Discovery of a novel TFEB activator targeting lysosomal dysfunction in amyotrophic lateral sclerosis using artificial intelligence-based virtual screening - PubMed
7 hours ago
- #TFEB activator
- #AI screening
- #neurodegenerative diseases
- Lysosomal dysfunction is a key feature in neurodegenerative diseases like ALS.
- TFEB is a target for restoring lysosomal health; AI screening identified isoginkgetin (ISO) as a potent TFEB activator.
- ISO promotes lysosomal biogenesis, enhances function, and shows neuroprotective effects in ALS models.
- The study validates AI-driven screening as a paradigm for discovering therapies against ALS and similar diseases.